News | News By Subject | News by Disease News By Date | Search News

Rheumatoid arthritis News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Going Up Against AbbVie (ABBV)'s Humira, Johnson & Johnson (JNJ) Presents Less-Than-Stellar Phase III Data     11/14/2016
OUCH! FDA Spurns Regeneron (REGN), Sanofi (SNY)'s RA Drug Over Plant Deficiencies     11/1/2016
Deficiencies Found at Manufacturing Site Could Delay Approval of Sanofi Genzyme (SNY)'s Next Blockbuster     10/31/2016
AbbVie (ABBV) Abandons Arthritis Pact With Ablynx (ABLYF)     10/20/2016
3 Healthcare Giants Are All Trying to Take a Bite Out of AbbVie (ABBV)'s Humira Domination     10/14/2016
FDA Clears Amgen (AMGN) Copy of AbbVie (ABBV)'s Blockbuster Humira     9/26/2016
Ablynx (ABLYF) Reports Compelling Topline Phase Ilb Study Results With Its Anti-Il-6r Nanobody, Vobarilizumab, In RA Patients, Confirming Its Best-In-Class Potential     8/9/2016
GlaxoSmithKline (GSK) Becomes First Drug Firm to Use Apple (AAPL)’s ResearchKit for Clinical Research     7/18/2016
Amgen (AMGN) Inches Closer to Selling Cheaper Version of AbbVie (ABBV)'s Blockbuster Humira     7/13/2016
FDA Staff Says Novartis AG (NVS) Copy of Amgen (AMGN)'s Blockbuster Enbrel is 'Highly Similar'     7/11/2016
AbbVie (ABBV)'s $175 Million Gamble Pays Off as Ablynx (ABLYF) RA Drug Meets Goal in Phase II Study     7/8/2016
FDA Staff Says Amgen (AMGN) Biosimilar is 'Highly Similar' to AbbVie (ABBV)'s Blockbuster Humira     7/8/2016
Investors Look to the Future of AbbVie (ABBV) Post-Patent Protection for Humira     7/8/2016
GlaxoSmithKline (GSK), Johnson & Johnson (JNJ)'s Rheumatoid Arthritis Drug Meets Goals in Large Late-Stage Study     6/8/2016 Approves Celltrion (068270.KQ)’s INFLECTRA, the First Cheaper Version of Johnson & Johnson (JNJ) Blockbuster Remicade     4/7/2016

News from Around the Web
Vagus Nerve Stimulation Significantly Reduces Rheumatoid Arthritis Symptoms, University of Amsterdam Study Shows     7/5/2016
Green Tea Compound May Block Rheumatoid Arthritis, Washington State University Study     2/17/2016
Occupational Textile Dust Exposure Linked To Rheumatoid Arthritis, Study Published In BMJ     1/15/2016
Your Diet May Determine Rheumatoid Arthritis Risk, Brigham and Women's Hospital Study     11/9/2015
Could Oral Contraceptives Help Ease Rheumatoid Arthritis? Rheumatism Research Centre Study     8/31/2015
Drug Flops From 2004 Haunt AstraZeneca PLC (AZN) Investors     5/23/2014
Chinese Herb As Effective As Arthritis Pain Drug, Annals of the Rheumatic Diseases Reveals     4/16/2014
Extra Pounds Linked to Rheumatoid Arthritis Risk in Women, Brigham and Women's Hospital, Harvard Medical School, Harvard School of Public Health Reveals     11/12/2012
Rheumatoid Arthritis Drugs May Help Curb Diabetes Development, Journal of the American Medical AssociationStudy Finds     6/22/2011
EULAR: Rituximab Plus Other Biologics Safe in RA     6/1/2011
Study Identifies Novel Role for a Protein That Could Lead to New Treatments for Rheumatoid Arthritis, Hospital for Special Surgery Study     5/23/2011
Lupus, Rheumatoid Arthritis May Raise Risk of Abnormal Heart Rhythm, University of Arkansas for Medical Sciences Study     5/9/2011
Recent Rituximab Trial with TNF Inhibitors Reports No New Safety Risks in Patients with Rheumatoid Arthritis, Desert Medical Advances Study     3/8/2011
Smoking May Interfere With Rheumatoid Arthritis Treatment, Karolinska University Hospital Study     1/6/2011
New Rheumatoid Arthritis Response Score Validated, Karolinska Institute Study     1/3/2011

Press Releases
Momenta (MNTA) Announces Positive Top-Line Phase III Results For M923, A Proposed HUMIRA (Adalimumab) Biosimilar     11/29/2016
Mallinckrodt (MNK) Release: Study Addresses Possible Impact Of H.P. Acthar Gel On Use Of Corticosteroids Among Patients With Rheumatoid Arthritis, Lupus, And Dermatomyositis/Polymyositis     11/18/2016
Regeneron (REGN) And Sanofi (SNY) Present Results From Phase 3 MONARCH Study Of Investigational Sarilumab At American College of Rheumatology Annual Meeting     11/16/2016
Janssen R&D Release: New Phase 3 Monotherapy Study Of Sirukumab Versus Humira And Sirukumab Data In An Anti-TNF Refractory Population Reported In The Treatment Of Moderately To Severely Active Rheumatoid Arthritis     11/16/2016
UCB, Inc. (UCBJF.PK) Release: The Lancet Publishes First Head-To-Head Study Of CIMZIA (Certolizumab Pegol) And Humira (Adalimumab) In Bio-Naïve Rheumatoid Arthritis Patients     11/15/2016
Oncobiologics (ONSIU) Announces Presentation Of Final Data From Phase I Clinical Study Of ONS-3010 (HUMIRA Biosimilar)     11/14/2016
CEL-SCI (CVM) Reports Preclinical Data Showing LEAPS Vaccine Is Successful In Treating Rheumatoid Arthritis     11/14/2016
First Patient Enrolled In Mallinckrodt (MNK) Phase 4 Trial Of H.P. Acthar Gel For Rheumatoid Arthritis     11/14/2016
Janssen Biotech (JNJ) Release: Two Studies Reveal Differences In Real-World Treatment Patterns In Rheumatoid Arthritis Patients Taking REMICAD (infliximab) Compared To CT-P13 (infliximab biosimilar)     11/14/2016
Eli Lilly (LLY) Release: New Analyses Of Phase 3 Trials Show Improvements In Rheumatoid Arthritis Symptoms Following Treatment With Baricitinib Across Diverse Population Of Patients     11/14/2016
Crescendo Bioscience Announces Four Studies With Vectra DA Will Be Presented At The American College of Rheumatology 2016 Annual Meeting     11/14/2016
Pfizer (PFE) To Present Additional Research For XELJANZ (Tofacitinib Citrate) In Rheumatologic Diseases, Including Rheumatoid Arthritis And Psoriatic Arthritis     11/7/2016
Eli Lilly (LLY) Release: New Data From Pivotal RA-BEACON Study Show Significant Improvement In Patient-Reported Outcomes In Rheumatoid Arthritis Patients Treated With Baricitinib Compared To Placebo     11/3/2016
Advanced Orthopedics And Sports Medicine Institute: How Seasonal Temperature Changes Can Affect Arthritis     10/27/2016
Boehringer Ingelheim's Adalimumab Biosimilar Candidate Shows Similar Efficacy And Safety Profile To Humira In Pivotal Phase III Study     10/26/2016